What Alfred Research Alliance does

Alfred Research Alliance (ARA) is a not-for-profit research consortium established in 1995 (as AMREP, renamed in 2016) that brings together eight member organizations co-located on the Alfred Hospital precinct in Melbourne, Australia. Its members conduct biomedical, clinical, and public health research spanning infectious disease, cardiovascular and metabolic disease, neuroscience, cancer, and population health. The alliance functions as a coordination and shared-infrastructure platform rather than a direct employer of researchers, with the central entity reporting 11-50 staff while supporting approximately 1,328 students on campus and a broader research workforce distributed across member institutes.

ARA's core capabilities rest on shared translational infrastructure: 31 clinical trial units hosting 748+ active trials with ~7,000 patients enrolled, multiple long-running biobanks (including ASPREE and AusDiab), a Total-Body Quadra PET scanner installed in 2025 (A$24M), GMP-certified bioanalytical services (historically via 360biolabs, now divested to BioAgilytix), and early-phase clinical trial capacity through member Nucleus Network, which expanded to the UK via the 2025 acquisition of Hammersmith Medicines Research. Alliance researchers produce on the order of 2,800 peer-reviewed publications per year and apply AI/ML in cardiology (Prof Tom Marwick) and epilepsy (Prof Patrick Kwan), among other areas.

The alliance's revenue mechanics are predominantly grant-based rather than commercial: A$332M in external research funding flowed through members in 2025, including A$42.9M in NHMRC Investigator Grants, supplemented by commercial clinical trial services (Nucleus Network as a global early-phase CRO), philanthropy (Gates Foundation malaria work), and partnership-based funding (e.g., the 2026 VARAP Aboriginal Health Accord). Customer relationships span federal research funders, international philanthropy, pharma sponsors, patients, and students, with no single counterparty dominating. Governance is in the process of transitioning to Bayside Health, the entity formed by the merger of Alfred Health and ARA effective January 2026.

Name

Alfred Research Alliance

Legal name

Alfred Research Alliance

Website

https://alfredresearchalliance.org.au

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Alfred Research Alliance is a not-for-profit consortium of eight Melbourne-based research organizations conducting biomedical, clinical, and public health research. It coordinates 31 clinical trial units running 748+ trials, supports ~7,000 patients and 1,328 students, and channels A$332M in annual external research funding.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Biomedical research
• Clinical trials
• Translational medicine
• Public health research
• Preclinical imaging

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Research Grants and Funding: The alliance generates revenue through competitive research grants from government bodies including NHMRC, Medical Research Future Fund, and other national/international funding bodies. Alliance members secured $332M in total external funding in 2025.
2. Clinical Trial Services: Revenue generated through contract research services via member organizations like 360biolabs and Nucleus Network for pharmaceutical and biotech companies conducting clinical trials.
3. Education and Training: Revenue from postgraduate education, nursing and allied health programs, and short courses offered by member universities.
4. Platform Services and Facilities Access: Fee-for-service access to specialized research platforms including imaging, cytometry, bioinformatics, and histology facilities for external researchers and industry.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Alfred Research Alliance is a consortium of eight healthcare, university, and medical research organizations operating a co-located biomedical research precinct in Melbourne. It delivers translational research, clinical trials (including first-in-human studies), specialized research platform services (flow cytometry, preclinical imaging, biobanks, bioinformatics), and postgraduate education programs. Activities span basic science, clinical trials, and public health implementation, supported by $332M in annual external research funding.

Product overview

Alfred Research Alliance is a collaborative research partnership among eight leading healthcare, education, and medical research organizations (Alfred Health, Monash University, Baker Heart and Diabetes Institute, Burnet Institute, Deakin University, La Trobe University, Nucleus Network, and 360biolabs) operating across a single research precinct in Melbourne. Rather than a unified software product, the Alliance provides a portfolio of shared research infrastructure, capabilities, and services including: specialized research platforms (ARAFlowCore for flow cytometry, ARA-MBI Preclinical Imaging Facility with MRI/PET/CT/MPI, Translational Cardiology Centre, Optima decision science tools); biobanks and clinical registries (ASPREE, AusDiab, Victorian HIV Bank, Alfred Cancer Biobank, Alfred Neuroscience Bio-databank); clinical trials services (748 trials across 31 units); education programs (postgraduate, nursing, allied health); and the Innovation & Education Hub (HUB spaces). These integrated capabilities enable translational research from basic science through to clinical application, positioning the precinct as one of Australia's largest biomedical research centers.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Services End-to-end clinical trials services spanning all phases from Phase I first-in-human studies through to late-stage and public health implementation, accessible across 31 clinical trial units. Supports pharmaceutical, biotech, and academic sponsors with experienced clinicians and patient access.
• Education Programs Comprehensive education offerings including postgraduate study, nursing and allied health programs, short courses, and scholarships/honours programs delivered through member universities. Bridges academic theory and real-world healthcare with 1,328 students welcomed to campus in 2025.
• Clinical Registries and Biobanks Collection of specialized biobanks including ASPREE Healthy Ageing Biobank, AusDiab study, Victorian HIV Blood and Tissue Storage Bank, Alfred Brain Tumour Bio-databank, Alfred Cancer Biobank, and Alfred Neuroscience Bio-databank supporting population health and clinical research.
• ARAFlowCore (Flow Cytometry Services) World-class flow cytometry services providing cell sorting and analysis in PC2-compliant laboratories, with spectral technology capable of visualizing 40+ fluorescent parameters on a single cell.
• ARA-MBI Preclinical Imaging Facility State-of-the-art preclinical imaging facility including 9.4T MRI, NanoPET-CT imaging system, and world-first magnetic particle imaging (MPI) system paired with localized hyperthermia for small animal research imaging.
• Translational Cardiology Centre Highly specialized cardiac research platform with expertise in myocardial infarction, cardiac arrest, and heart failure models, featuring state-of-the-art surgical and imaging technologies for preclinical trial design and delivery.
• Optima Decision Science Tools Mathematical modeling suite for public health decision-making developed in partnership with the World Bank. Open-access web-based tools for resource allocation optimization in HIV, hepatitis C, COVID-19, nutrition, tuberculosis, malaria, and maternal/child health.
• Bioinformatics Program Baker Heart and Diabetes Institute's bioinformatics capability providing data analysis across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics using statistical analysis, machine learning, and network analysis.
• HUB Innovation & Education Spaces Innovation and education hub featuring Town Square for collaboration, Learning Zone with technology-enabled flexible learning areas, The Terraces seminar space, and Ian Potter Reading Room quiet library space.
• ACRF Centre for Dynamic Immuno-Oncology Australian Cancer Research Foundation-funded center at the Paula Fox Melanoma and Cancer Centre advancing immunotherapy as a leading form of cancer treatment through understanding patient unique immune responses in real-time.
• Baker Heart & Diabetes Institute Research Research focused on heart disease, diabetes, and related conditions using ground-breaking bioengineering techniques, novel disease prediction and detection methods, and big data and AI approaches for better prevention, diagnosis, and treatment.

Quantifiable outcome

• 748 clinical trials open across 31 clinical trial units including 120 first-in-human studies
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Partnerships

13 partnerships are on record, tiered core and minor.

• BioAgilytix LabscoreStrategic or Co-development PartnerBioAgilytix Labs, headquartered in North Carolina with labs in Boston and Hamburg, acquired 360biolabs in 2021. 360biolabs was majority owned by Burnet Institute and received several hundred million dollars in revenue from the sale. The acquisition adds to BioAgilytix's international presence and quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP) in Melbourne.
• Hammersmith Medicines ResearchminorStrategic or Co-development PartnerNucleus Network acquired Hammersmith Medicines Research, extending their footprint from Australia and US into the UK, strengthening early-phase clinical trial capabilities globally.
• Kenya Medical Research InstitutecoreStrategic or Co-development PartnerInternational research collaboration with Prof James Beeson and Burnet's Malaria Immunity and Vaccines Group to conduct clinical studies in East Africa identifying antibodies for malaria vaccine development.
• Infectious Diseases Research Collaboration (Uganda)coreStrategic or Co-development PartnerInternational collaboration led by Isaac Sewanyana for malaria vaccine research studies in Uganda, part of Gates Foundation funded projects.
• Imperial College LondoncoreStrategic or Co-development PartnerCollaboration with Prof Faith Osier from Imperial College London on malaria vaccine development research in East Africa.
• Stanford UniversitycoreStrategic or Co-development PartnerCollaboration with Pras Jagannathan from Stanford University on malaria vaccine development research.
• PATHcoreStrategic or Co-development PartnerPartnership with PATH, a US-based not-for-profit organization, on global health vaccine development initiatives.
• marra ngarrgoo, marra goorri (VARAP)coreStrategic or Co-development PartnerIn early 2026, Alfred Research Alliance became a signatory to the Victorian Aboriginal Health, Medical and Wellbeing Research Accord Project (VARAP), an innovative framework designed to guide and govern health research impacting Aboriginal and Torres Strait Islander people in Victoria.
• University of MelbournecoreStrategic or Co-development PartnerPartnership with University of Melbourne in the Pathway to Clean Indoor Air project consortium, with Prof Jason Monty leading the engineering domain.
• THRIVE (Training Centre for Advanced Building Systems Against Airborne Infection Transmission)coreStrategic or Co-development PartnerPartnership with THRIVE in the Pathway to Clean Indoor Air project to evaluate indoor air quality and develop solutions for airborne infection transmission.
• Amazon Web Services (AWS)minorStrategic or Co-development PartnerAWS collaborated with the consortium to establish practical steps for an integrated indoor air quality solution, bringing real-time air quality monitoring network experience.
• Burnet InstitutecoreStrategic or Co-development PartnerBurnet Institute is majority owner of 360biolabs and receives revenue from the sale to BioAgilytix. Burnet Institute is a foundation partner of the Australian Institute for Infectious Disease (AIID).
• Australasian Leukaemia and Lymphoma GroupcoreStrategic or Co-development PartnerALLG is a not-for-profit blood cancer clinical trial research group that partnered with Prof David Curtis on blood stem cell transplant research that changed 40 years of standard practice.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Brisbane Diamantina Health Partners: NHMRC-accredited AHSC covering Brisbane's major hospitals and universities (UQ, QUT). Competes with ARA for translational research scale and industry-sponsored trials in Australia.
• Parkville Precinct Partnership (WEHI, Peter Mac, Doherty Institute, Melbourne Neuroscience Centre): Major Melbourne biomedical research cluster around Walter and Eliza Hall Institute, Peter MacCallum Cancer Centre, and the Doherty Institute. Comparable in scale to ARA, focused on cancer, immunology, and infectious disease, offering an alternative precinct for researchers and industry CRO partnerships.
• King's Health Partners (London): UK-based academic health science centre combining King's College London, Guy's and St Thomas', King's College Hospital, and South London and Maudsley. Closest international analog to ARA's AMC-affiliated consortium structure with translational research focus.
• Monash Partners Academic Health Science Centre: NHMRC-accredited AHSC spanning Monash Health, Monash University, Hudson Institute, and other partners. Overlaps significantly with ARA given Monash University's dual membership; competes for translational research funding and clinical trial activity in Melbourne.
• Melbourne Academic Centre for Health (MACH): MACH is a Victorian NHMRC-accredited Advanced Health Research and Translation Centre linking several Melbourne hospitals and universities — the same AMC-affiliated consortium model as ARA. Directly comparable as a competing Melbourne-based academic health science partnership focused on translational research.
• Sydney Health Partners: NHMRC-accredited AHSC bringing together several Sydney-based hospitals, universities, and research institutes. Closest geographic peer for translational research funding and clinical trial competition in Australia's largest metro market.

Emerging players

• Francis Crick Institute: London-based biomedical discovery research institute with strong translational focus and major funder partnerships (Wellcome, CRUK, MRC). Comparable in biomedical research density and public-private funding model, though structured as a single institute rather than a consortium.

Regional players

• South Australian Health and Medical Research Institute (SAHMRI): Major state-based biomedical research institute in Adelaide that similarly aggregates research infrastructure, clinical trial activity, and university partnerships. Operates in a different metro market but is structurally analogous as a multi-stakeholder research enterprise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alfred-research-alliance
• Xx.com/Alfred_Research

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alfred Research Alliance